echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAMA: AstraZeneca, Janssen/Johnson & Johnson COVID-19 vaccine causes cerebral venous sinus thrombosis and thrombocytopenia to add new evidence

    JAMA: AstraZeneca, Janssen/Johnson & Johnson COVID-19 vaccine causes cerebral venous sinus thrombosis and thrombocytopenia to add new evidence

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, it has been reported that within 4 to 28 days after vaccination with the new coronary pneumonia vaccine ChAdOx1 nCov-19 (AstraZeneca/Oxford) and AD26.


    Recently, it has been reported that within 4 to 28 days after vaccination with the new coronary pneumonia vaccine ChAdOx1 nCov-19 (AstraZeneca/Oxford) and AD26.


    Mayte Sánchez van Kammen and others discussed the incidence of thrombocytopenia, heparin-induced thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis before the new coronary pneumonia epidemic


    Of the 952 patients, 865 had a baseline platelet count available


    Of the 952 patients, 865 had a baseline platelet count available


    The main outcome measures were admission thrombocytopenia (platelet count <150×10 3 /μL), heparin-induced thrombocytopenia ( diagnosed by the treating doctor ) and platelet factor 4/heparin IgG antibody (optical density> 0.


    The platelet count of 56 patients with cerebral venous sinus thrombosis and thrombocytopenia on admission and discharge

    The platelet count of 56 patients with cerebral venous sinus thrombosis and thrombocytopenia on admission and discharge

    Among 865 patients (median age 40 years old [interquartile range 29 to 53 years old], 70% women), 73 cases of thrombocytopenia (8.


    Among 865 patients (median age 40 years old [interquartile range 29 to 53 years old], 70% women), 73 cases of thrombocytopenia (8.


    In this study, thrombocytopenia was not common in 865 patients with CVST before the COVID-19 pandemic


    In patients with cerebral venous sinus thrombosis before the new coronary pneumonia epidemic, baseline thrombocytopenia is uncommon, and heparin-induced thrombocytopenia and platelet factor 4/heparin antibody are rare.


     Original source

    Sánchez van Kammen M, Heldner MR, Brodard J, et al.


    Sánchez van Kammen M, Heldner MR, Brodard J, et al.
    Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic.
    JAMA.
    2021;326(4):332– 338.
    doi:10.
    1001/jama.
    2021.
    9889 Sánchez van Kammen M, Heldner MR, Brodard J, et al.
    Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic.
    JAMA.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.